A couple of interesting points in this presentation
- • 1Q FY21 on track to report sales growth of +25% above 4Q FY20
- Can now sell to select customers in the US under a section lVc exemption until FDA EUA is received
- Targeting first US customer contract for SARS-COV2 product
A couple of interesting points in this presentation- • 1Q FY21...
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.5¢ |
Change
-0.015(2.05%) |
Mkt cap ! $162.2M | |||
| Open | High | Low | Value | Volume |
| 73.0¢ | 73.0¢ | 71.0¢ | $44.71K | 62.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 481 | 71.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 72.5¢ | 1783 | 2 |
View Market Depth
| Last trade - 13.27pm 13/09/2024 (20 minute delay) ? |
| GSS (ASX) Chart |